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Abstract
Background: Bacillus anthracis has two major virulence factors: a tripartite toxin that produces
lethal and edema toxins and a polyglutamic acid capsule. A recent report suggested that a toxin
belonging to the cholesterol dependant cytolysin (CDC) family, anthrolysin O (ALO) was a new
virulence factor for B. anthracis but subsequent studies have questioned its relevance in
pathogenesis. In this study, we examined the immunogenicity of recombinant anthrolysin O (rALO)
in mice.
Results: BALB/c mice immunized with rALO and boosted after two weeks, produce sera with
strong Ab responses with a predominance of IgG1 and IgG2a. Five hybridomas to rALO were
recovered representing the IgM, IgG1, and IgG2b isotypes. Passive administration of 3 of the five
monoclonal antibodies (mAbs) to rALO prior to infection with lethal intravenous (i.v.) B. anthracis
Sterne strain infection in mice was associated with enhanced average survival and a greater
likelihood of surviving infection. A combination of two mAbs to ALO was more effective than
either mAb separately. One mAb (64F8) slowed the toxicity of rALO for J774.16 macrophage-like
cells.
Conclusion: Our results suggest that ALO contributes to the virulence of B. anthracis Sterne
strain in this infection model and that Ab response to ALO may contribute to protection in certain
circumstances.
Background
Bacillus anthracis is gram-positive bacterium that is the
causative agent of anthrax, a fulminant disease of grazing
animals. In recent years, B. anthracis has emerged as a
major biological weapon as evidenced by the casualties
and disruption caused in 2001 by distribution of the
spores through the U.S. Mail. Consequently, there is great
interest in understanding its pathogenesis as well as in the
development of countermeasures to prevent and/or treat
disease. B. anthracis has two well-studied virulence factors:
a polyglutamic acid capsule and a tripartite toxin that
comprises lethal toxin (LT) and edema toxin (ET). Ab-
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mediated immunity neutralizes these toxins as evidence
for reduced susceptibility after immunization with
anthrax toxin and/or capsular antigens.
In addition to LT and ET, B. anthracis expresses several
other toxins including a cholesterol-dependent cytolysin
(CDC) known as anthrolysin O (ALO) [1]. The CDC class
of toxins includes listeriolysin O, perfringolysin O, and
streptolysin O, in Listeria, Clostridia, and Streptococcus spp,
respectively. Given that CDCs are important virulence fac-
tors for Gram positive bacteria, ALO was initially consid-
ered to be a potential virulence factor [1] and a role in
pathogenesis was envisioned from the observation that it
interacted with Toll-like receptor 4 [2]. Furthermore, B.
anthracis ALO kills neutrophils and macrophages in vitro
[3]. However, a comparison of ALO-deficient and wild-
type strains in an inhalation anthrax model revealed no
difference in virulence, suggesting that this toxin was not
essential for virulence [4]. Consistent with this observa-
tion, immunization with ALO protects mice against the
toxin but not infection with B. anthracis [5]. Hence, the
current view is that ALO is a potent cytotoxin in vitro that
has not been demonstrated to have a significant role in
virulence.
In this study we revisited the role of ALO in virulence by
generating mAbs to recombinant ALO and employing
them in passive protection experiments. We report the
generation of five mAbs that differ in their efficacy for
toxin neutralization in vitro and their ability to prolong
survival in mice infected with B. anthracis. These results
are interpreted as implying that ALO contributes to the
pathogenesis of anthrax, at least in experimental murine
intravenous infection.
Results
Immunogenicity of rALO
rALO was emulsified in complete Freund's adjuvant and
five BALB/c mice were injected with either 1 or 10 μg/
mouse. All mice responded to immunization with a
serum Ab response to rALO although there were signifi-
cant individual differences among mice in the magnitude
of the response (Figure 1). At two weeks, mice were
boosted with the same amount of rALO in incomplete
Freund's adjuvant. The anti-rALO response was boosted
with subsequent immunization. The Ab response was
composed mainly of IgG1 and IgG2a, with significantly
smaller amounts of IgG2b and IgG3, and very little IgA
and IgM (Figure 2). The mouse with the highest anti-ALO
Ab titer (mouse M9, Figure 1B) was selected for spleen
harvest and hybridoma generation. Five mAbs were recov-
ered; three IgMs (53C2, 62F7 and 80C9), one IgG1 (64F8)
and one IgG2b (16G2).
Specificity studies
The mAbs generated were tested for their ability to bind
rALO by ELISA and immunoblot (Figures 3 and 4). Three
of the mAbs (16G2, 62F7, and 64F8) manifested signifi-
cantly higher levels of reactivity with rALO by ELISA than
the other two (53C2 and 80C9) (Figure 3). To obtain
some information on the specificity of these mAbs com-
petition ELISAs were carried out with different pairwise
combinations of Abs. mAb 80C9 (IgM) and mAb 64F8
(IgG1); mAb 53C2 (IgM) and mAb 16G2 (IgG2b); mAb
62F7 (IgM) and mAb 64F8 (IgG1); mAb 80C9 (IgM) and
Mab 16G2(IgG2b); mAb 53C2(IgM) and mAb
64F8(IgG1); mAb 62F7(IgM)and 16G2(IgG2b). None of
the mAbs inhibited the binding of any other mAb, imply-
ing that each of these pairs binds to a different epitope
(data not shown). Immunoblot analysis revealed that all
five mAbs bound to rALO and to ALO from lysed B.
anthracis cells and their culture supernatants (Fig 3). How-
ever, the intensity of the mAb reactivity with rALO by
immunoblot varied with mAbs 16G2 and 64F8 producing
significantly stronger signals than the rest of the mAbs.
The intensity of the reactivity with ALO produced by the
Sterne strain was strongly recognized by mAb 62F7 and
weakly by the rest of the mAbs.
In vitro neutralizing activity
Given that ALO is cytotoxic in vitro, we examined whether
the various anti-rALO mAbs could reduce killing of mac-
rophages by rALO in vitro. These experiments necessarily
involved measuring toxicity after relatively short incuba-
tion times because of the rapid lytic action of rALO. MAb
antitoxic activity was assessed by an in vitro assay wherein
cell viability was measured by trypan blue staining. Only
mAb 64F8 manifested in vitro toxin neutralizing activity
(50% cell viability compared to the other mAbs and irrel-
evant Ab).
Survival studies
To evaluate the protective efficacy of the anti-rALO mAbs
in vivo, we administered mAbs i.p. 2 h to 3 h prior to intra-
venous infection with B. anthracis. A total of 6 independ-
ent passive Ab experiments were performed. MAbs 16G2
and 62F7 showed no protection in any of the survival
studies while mAbs 53C2 (Table 1), 64F8 and 80C9
revealed a moderate level of protection (Figure 5). We
selected a dose of 0.1 mg/mouse after noting that larger
doses were either not more effective or were associated
with reduced protection in prozone-like effects (Table 1).
In the majority of experiments, mAbs 64F8 and 80C9
were associated with modest but statistically significant
prolongations in survival relative to groups receiving an
irrelevant mAb or PBS. The proportion of mice surviving
B. anthracis challenge was 20% (32/128) in mice receiving
anti-ALO mAbs compared to 8% (4/50) in control groups
receiving either PBS or an irrelevant Ab surrogate (P =BMC Microbiology 2008, 8:159 http://www.biomedcentral.com/1471-2180/8/159
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0.049). The combination of mAbs 64F8 and 80C9 was
more effective than either mAb alone in prolonging sur-
vival (Table 1). The protection observed with passive
administration of mAbs to ALO was lower than observed
for a previously described neutralizing mAb to PA (Figure
5). Passive administration of mAbs to PA (mAb 7.5G) and
ALO (mAb 64F8) revealed that their effect on survival was
not additive or synergistic in this system (Fig 5). Serum
from moribund animals manifested reactivity with ALO
indicating that the enzyme is made during the course of
infection, that it is immunogenic, and that a brisk Ab
response is apparent by day 4 of infection (Figure 6).
Discussion
The role of ALO in B. anthracis pathogenesis is uncertain
because ALO-deleted strains have not manifested reduced
virulence relative to ALO competent strains. Furthermore,
a vaccination study with an ALO toxoid vaccine revealed
that immunization protected against toxin challenge but
not B. anthracis infection [5]. In this study, we have revis-
ited the role of ALO in B. anthracis pathogenesis by mak-
ing mAbs to rALO and assessing their ability to modify the
course of lethal infection in mice. Since immune
responses often target and negate the function of virulence
factors such as toxins and capsules, the ability to demon-
A. Antibody (Ab) response of mice immunized with recombinant anthrolysin (rALO) after initial immunization at day 14 as  determined by ELISA Figure 1
A. Antibody (Ab) response of mice immunized with recombinant anthrolysin (rALO) after initial immuniza-
tion at day 14 as determined by ELISA. Immunization was done with complete Freund's adjuvant. Serum dilution is rep-
resented by different fill patterns. B. Ab response after mice were boosted with same amount toxin in incomplete Freund's 
adjuvant measured at day 28. Individual mouse are denoted by M and numbers 1 to 10. Mice 1–5 received 1 μg of rALO and 
mice 6–10 received 10 μg of rALO. Pre-bleed is serum from mouse 10 before immunization and was used as control in panels 
A and B. Alkaline phosphatase conjugated goat anti-mouse IgG (AP-GAM-IgG) alone was used a negative control (NS: no 
serum) for A and B. Inset, ELISA configuration for both figures whereby rALO is absorbed on polystyrene plates and the pres-
ence of specific Ab to rALO is detected with AP-GAM-IgG.
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strate that active and/or passive immunity to a particular
microbial component can mediate protection is a time-
honored method for establishing the importance of that
component in virulence. Using standard hybridoma tech-
nology, we generated five mAbs to ALO. We demonstrated
that passive administration of three of these mAbs before
infection prolonged average mouse survival after lethal B.
anthracis infection and significantly increased individual
mouse survival after inoculation. The average increase in
survival time observed after passive administration of
anti-ALO mAbs was shorter than that observed after
administration of neutralizing mAb to PA. Based on these
results we conclude that ALO contributes to the overall
virulence phenotype of B. anthracis Sterne strain with the
caveat that the relative contribution of this toxin is proba-
bly significantly less than that of other well-established
virulence factors such as LT, ET and capsule, possibly
because these bacteria expresses redundant phospholi-
pases [4]. Since the overall virulence phenotype of a path-
ogenic microbe is a function of the combination of its
virulence attributes, it is possible that ALO makes a dis-
proportionately greater contribution to virulence for the
B. anthracis Sterne strain because this strain lacks a cap-
sule. This conclusion does not negate the fact that no dif-
ference in virulence was found for ALO-deficient and –
sufficient B. anthracis strains [4], since the contribution of
ALO to virulence may not be sufficient to manifest itself
in that comparison. Determining the relative contribution
of ALO to the overall virulence B. anthracis virulence phe-
notype cannot be estimated from this data, but such infor-
mation may be obtained by regression analysis of
multiple strains that differ in virulence factor expression
[7,8].
Our results also shed some light on the difficulties associ-
ated with demonstrating a protective role for ALO toxoid
immunization [5]. Of the five mAbs tested in this study,
two were not protective indicating that ALO immuniza-
tion elicited both protective and non-protective antibod-
ies. In other systems non-protective Abs can interfere with
the function of protective Abs [9,10]. In our passive pro-
tection experiments, we used a relatively large dose of Ab
to obtain a modest survival effect. If B. anthracis is phago-
cytosed rapidly after i.v. infusion this large dose may
reflect a requirement for high serum concentration to
mediate intracellular effects as has been demonstrated for
Ab efficacy against Listeria monocytogenes [11,12]. Another
finding that may obscure differences between immunized
Isotype composition of Ab response of mice immunized with rALO Figure 2
Isotype composition of Ab response of mice immunized with rALO. Serum from M6–M10 was analyzed for isotype 
Ab response to rALO. Serum was diluted 1:100. The different isotypes were represented by different fill patterns. Inset 
denotes ELISA configuration whereby rALO is absorbed on polystyrene plates and the presence of specific Ab to rALO is 
detected with AP-GAM-IgG. Pre-bleed 1 and 2 are from M9 and M10 before immunization with rALO.
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and non-immunized hosts is that B. anthracis infection led
to a rapid Ab response to ALO, thus diminishing the time
window when there is a difference between immune and
naïve hosts to the first few days of infection. It is notewor-
thy that moribund mice had measurable Ab to ALO
implying that that the enzyme is expressed during infec-
tion and that an antibody response to this antigen is not
sufficient to confer survival. Although the mechanism of
antibody-mediated protection was not determined it is
likely that it involved interference with the action of
Anthrolysin. Consistent with this notion, one mAb exhib-
ited transient neutralizing activity in vitro. The negative
and/or modest effects toxin neutralizing effects may
reflect the inadequacy of antibody-mediated neutraliza-
tion given the fulminant nature of Anthrolysin-mediated
cell lysis in vitro (eg a false-negative effect with this assay).
It is noteworthy that 3 of the 5 mAbs recovered were IgM
despite the relatively scarcity of ALO-binding IgM in
immune sera. Dissociation between serum isotype com-
position and recovered hybridomas is not unusual, and
can reflect the fact that IgM half-life is in the order of
hours while that of IgG is up to 8 days in mice. IgM hybri-
domas may also be preferentially selected during screen-
ing because this isotype has higher avidity.
The combination of two protective mAbs (64F8 and
80C9) was more effective than when the mAbs were
administered singly. This observation implies that poly-
clonal preparations could be significantly more effective
than single mAbs. Similar reports of mAb synergy have
been reported in passive protection studies against pneu-
molysin [13] and other toxins [14,15]. The mechanism of
MAb binding to rALO by ELISA Figure 3
MAb binding to rALO by ELISA. MAbs isolated were examined for their binding abilities to rALO. ELISA configuration 
includes absorbing rALO onto polystyrene plates and specific Ab binding to rALO is detected with AP-GAM-IgG. Diagram 
illustrates the ELISA configuration.
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
30.0000 10.0000 3.3333 1.1111 0.3704 0.1235 0.0412 0.0137 0.0045 0.0015 0.0005 0.0002
 rALO (ug/ml)
A
b
s
o
r
b
a
n
c
e
 
(
4
0
5
n
m
)
mAb16G2 mAb 53C2 mAb 62F7 mAb 64F8 mAb 80C9
AP-GAM - Ig 
specific
rALO
mAbBMC Microbiology 2008, 8:159 http://www.biomedcentral.com/1471-2180/8/159
Page 6 of 10
(page number not for citation purposes)
Ab action in vivo is unclear. One of the three protective
mAbs (mAb 64F8) delayed cell death for macrophages
treated with ALO in vitro, suggesting that the mechanism
of protection for this mAb could be toxin neutralization.
For mAb 16G2, immunoblot binding studies revealed
strong binding to rALO but no binding to B. anthracis
expressing surface ALO. Hence, for this mAb the lack of
protective efficacy could reflect an inability to bind to
natively expressed B. anthracis ALO. We noted differences
in the reactivity of mAbs with rALO and ALO from B.
anthracis lysates. This observation implies antigenic differ-
ences between natively expressed B. anthracis and E. coli
rALO that could reflect differences in conformation and/
or structure between these proteins
Conclusion
In summary, we report the generation of first mAbs to
ALO and demonstrate that some confer protection in pas-
sive protection experiments against a non-encapsulated B.
anthracis  strain. This result suggests that eliciting Ab
responses to ALO or providing antibodies passively could
have clinical applications in prevention or therapy of
anthrax. The finding that some mAbs prolong survival
and that combinations of these mAbs are more effective
than single mAbs suggests that it may be possible to iden-
tify more effective immunoglobulin preparations for use
in prophylaxis and therapy. The observation that admin-
istration of Ab to ALO was associated with reduced mor-
tality implies that ALO contributes to the virulence of B.
Immunoblot analysis of mAb binding to rALO and B. anthracis Sterne strain Figure 4
Immunoblot analysis of mAb binding to rALO and B. anthracis Sterne strain. rALO, culture supernatant, and lysed 
bacterial cells were solubilized in Laemmli sample buffer, run under denaturing conditions and were separated on a 10% SDS-
PAGE. The blots were incubated with rALO specific mAbs and isotype specific GAM secondary Ab conjugated to HRP. MW, 
molecular weight marker; +, rALO; P, lysed bacterial cells; S, culture supernatant. The expected molecular weight of rALO is 
approximately 53 Kd.
75 Kd
50 Kd
75 Kd
50 Kd
mAb 62F7 mAb 53C2 mAb 80C9 mAb16G2 mAb 64F8
MW    +     P     S MW    +      P    S MW  +      P     S MW   +      P     S MW    +       P     SBMC Microbiology 2008, 8:159 http://www.biomedcentral.com/1471-2180/8/159
Page 7 of 10
(page number not for citation purposes)
anthracis infection, although the magnitude of the contri-
bution ALO to the overall virulence phenotype remains to
be established.
Methods
Bacillus anthracis strain 34F2 (Sterne strain) and rALO
Bacillus anthracis Sterne strain 34F2 (pXO1+, pXO2-) was
obtained from Dr. Alex Hoffmaster at the Center for Dis-
ease Control (Atlanta, GA). Bacterial cultures were grown
in brain heart infusion (BHI) broth (Difco, Detroit, Mich)
at 37°C for 18 h while shaking. These conditions apply to
all experiments. Recombinant anthrolysin (rALO) was
expressed from E. coli as described [1].
Mice and immunization
Female BALB/c and A/JCr mice (6–8 weeks old) were
obtained from the National Cancer Institute (Bethesda,
MD). Mice were immunized intraperitoneally (i.p.) with
either 1 or 10 μg of rALO in complete Freund's adjuvant
(Sigma, St. Louis, MO) and boosted after two weeks with
1 and 10 μg in incomplete Freund's adjuvant. The mouse
with the highest anti-ALO serum titer was selected for gen-
erating hybridomas.
ELISA
Enzyme-linked immunosorbant assay (ELISA) was used
to determine serum Ab titers and mAb binding to rALO.
Briefly, 1 μg/ml of rALO in phosphate buffered saline
(PBS) was used to coat polystyrene microtiter plates. The
plates were blocked with 1% bovine serum albumin in
PBS (1%BSA/PBS). Microtiter plates were then incubated
with immune sera or hybridoma supernatants. Ab bind-
ing was detected using isotype specific alkaline-phos-
phatase (AP) labeled goat anti-mouse (GAM) Ab
Survival analysis of A/JCr mice infected with B. anthracis Sterne strain Figure 5
Survival analysis of A/JCr mice infected with B. anthracis Sterne strain. Mice were given 100 μg mAb intraperito-
neally 2–3 h prior to infection and infected intravenously with 104 bacterial cells. Mice were monitored daily for morbidity. The 
data shown represents pooling of six independent experiments using the same conditions.
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(Southern Biotechnology, Birminham, AL). Plates were
developed with p-nitrophenylphosphate (PNPP) sub-
strate (Sigma, St. Louis, MO). All incubations were done
at 37°C for 1 h. Absorbance was measured in a microplate
reader at 405 nm (Labsystems Multiskan). Competition
ELISAs were used to evaluate epitope specificity for the
mAbs generated. Briefly, differing amounts of one of the
mAbs was mixed with a constant amount of a second mAb
of a different isotype. The mixture was added to rALO
immobilized on a microtiter plate. After 1 h incubation at
37°C, the microplate was washed to remove excess
unbound Ab. Ab binding was detected with isotype-spe-
cific AP labeled GAM Ab followed by a second incubation
and wash. Detection was accomplished by the addition of
PNPP substrate and measurement of absorbance at 405
nm.
Generation of monoclonal antibodies
The mouse with the highest Ab titer was selected to gener-
ate Ab-producing hybridomas using previously estab-
lished methods [6]. Briefly, NSO myeloma cells were used
as fusion partners for the splenocytes from the immu-
nized mouse, at a ratio of 4:1. Seven to ten days later,
hybridoma supernatants from clones were screened by
ELISA as described above for the presence of mAbs to
rALO. Positive clones were selected and stabilized by clon-
ing twice in soft agar. ELISA was used to determine the iso-
types of the murine mAbs by using isotype-specific
reagents.
SDS-PAGE and Western blots
rALO, culture supernatant, and lysed bacterial cells were
solubilized in Laemmli sample buffer and run under
denaturing conditions. After boiling samples for 10 min,
proteins were separated on a 10% SDS-PAGE. Proteins
were visualized by staining for 1 h with GelCode stain
(Pierce, Rockford, IL) and excess stain removed with
deionized water. After samples were separated, they were
transferred to a 0.20 μm nitrocellulose membrane and
blocked with 3% powdered milk in PBS. The blots were
incubated with the rALO specific mAbs, washed with 1%
BSA/PBS and incubated with isotype specific GAM sec-
Reactivity of serum from moribund mice lethally infected with B. anthracis Sterne strain Figure 6
Reactivity of serum from moribund mice lethally infected with B. anthracis Sterne strain. These mice were from 
control groups that did not receive passive mAb to rALO. Pre-bleed serum was collect from M1 and 2 before infection and 
was used at a dilution of 1:50. rALO (1 μg/ml) was used as the positive control. Ab titers were measured at day 4 of post-infec-
tion. Inset denotes ELISA configuration. M1 and 2 denotes mouse 1 and 2.
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ondary Ab conjugated to HRP. Proteins were visualized by
developing with a SuperSignal West Pico chemilumines-
cence kit (Pierce, Rockford, IL).
Cell viability studies
Trypan blue solution was used to identify J774 macro-
phages that had been lysed after exposure to rALO. Cells
(104) were added to 96-well plate and immediately added
85 ng diluted in PBS of rALO. The 96-well plate was incu-
bated for 30 min at 37°C and cell viability was visualized
by microscopic examination.
Survival studies
Six to eight week old A/JCr mice were injected i.p. with
0.1, 0.25, 0.5 or 1.0 mg of mAb 3 h prior to intravenous
(i.v.) infection with a lethal dose (104 bacterial cells) of B.
anthracis. Mice were monitored daily for mortality and
morbidity and deaths recorded.
Statistical analysis
Survival analysis was done by log rank censoring long
term survivors. The chi square statistic (p < 0.05) was used
to determine the significance between groups.
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